Loading…
NanoViricides, Inc. is projected to rise to $1.84 by 2027, a +19% move from its current price of $1.55. NNVC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.49 | $1.55 | $1.62 | -0.04% |
| Aug 6 | $1.46 | $1.55 | $1.64 | -0.07% |
| Aug 7 | $1.44 | $1.55 | $1.66 | -0.11% |
| Aug 8 | $1.42 | $1.55 | $1.68 | -0.15% |
| Aug 9 | $1.41 | $1.55 | $1.70 | -0.19% |
| Aug 10 | $1.40 | $1.55 | $1.71 | -0.22% |
| Aug 11 | $1.39 | $1.55 | $1.73 | -0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.39 | $1.55 | $1.73 | -0.26% |
| Week 2 | $1.32 | $1.54 | $1.80 | -0.52% |
| Week 3 | $1.27 | $1.54 | $1.86 | -0.78% |
| Week 4 | $1.23 | $1.53 | $1.91 | -1.04% |
| Week 5 | $1.20 | $1.53 | $1.96 | -1.30% |
| Week 6 | $1.17 | $1.53 | $2.00 | -1.56% |
| Week 7 | $1.14 | $1.52 | $2.03 | -1.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NanoViricides, Inc. is a healthcare company described as a clinical stage nano-biopharmaceutical firm that discovers, develops, and commercializes drugs to combat viral infections. Its product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc.
was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NanoViricides, Inc. (NNVC) is a healthcare stock with a current price of $1.61 and a market cap of $41.05M, ranking 4432. The stock sits in a specific market position reflective of its micro-cap profile. The latest 30-day trading activity shows a range from $1.20 to $2.16, with a technical setup showing bullish momentum.
A major floor 43.9% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 14.2% above — a clean break opens room to run.
A major ceiling 29.0% above — clearing it would confirm fresh momentum.
Key NNVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NNVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.55 | Sell | $1.54 | Buy |
| MA 10 | $1.56 | Sell | $1.56 | Sell |
| MA 20 | $1.60 | Sell | $1.56 | Sell |
| MA 50 | $1.51 | Buy | $1.50 | Buy |
| MA 100 | $1.36 | Buy | $1.41 | Buy |
| MA 200 | $1.30 | Buy | $1.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.48 | Neutral |
| Stoch RSI (14) | 10.93 | Buy |
| CCI (20) | -59.90 | Neutral |
| Williams %R (14) | -86.21 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -11.63 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 13.79 | Buy |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 48.48 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.55 | Sell |
| ADX (14) | 10.08 | Neutral |
| ATR (14) | 0.06 | Info |
Technical sentiment is BULLISH with RSI(14) at 50. The stock trades near the SMA50 of $1.51 and above the SMA200 of $1.30, suggesting a near-term uptrend. Support is seen at $1.22 and resistance at $1.77, defining a near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.85 | $1.55 | $2.03 | 0% | Neutral | |
| $1.40 | $1.84 | $2.60 | +19% | Neutral | |
| $1.53 | $2.11 | $3.14 | +36% | Bullish | |
| $1.37 | $1.95 | $3.03 | +26% | Bullish | |
| $1.63 | $2.41 | $3.87 | +56% | Bullish | |
| $2.24 | $3.42 | $5.66 | +121% | Bullish | |
| $2.52 | $3.96 | $6.72 | +156% | Bullish | |
| $2.64 | $4.27 | $7.40 | +175% | Bullish | |
| $2.58 | $4.29 | $7.60 | +177% | Bullish | |
| $2.67 | $4.56 | $8.24 | +194% | Bullish | |
| $4.18 | $8.05 | $15.81 | +420% | Bullish | |
| $8.17 | $18.14 | $39.99 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.85 | $1.55 | $1.87 | +0.00% |
| September 2026 | $1.22 | $1.47 | $1.83 | -5.20% |
| October 2026 | $1.23 | $1.50 | $1.89 | +1.95% |
| November 2026 | $1.28 | $1.57 | $2.01 | +4.71% |
| December 2026 | $1.27 | $1.56 | $2.03 | -0.31% |
Click any year to see its month-by-month NNVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NanoViricides, Inc.'s 2026 outlook centres on $1.55, within a $0.85 to $2.03 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NNVC could reach as high as $2.60, with a base case around $1.84 and support toward $1.40 — roughly +19% from $1.55. A consolidation phase looks the most probable path here.
Expect NNVC to range from $1.53 to $3.14 through 2028. The $2.11 average target implies a +36% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The NNVC price prediction for 2029 points to an average of $1.95 (low $1.37, high $3.03) — a potential gain of +26% on today's $1.55. Buyers look set to stay in control over this stretch.
In 2030, NNVC is projected to trade between $1.63 and $3.87, averaging $2.41 — a potential gain of +56% from today's $1.55. That is up +24% on the projected 2029 average. Momentum favours further upside here.
NanoViricides, Inc.'s 2031 outlook centres on $3.42, within a $2.24 to $5.66 range. That is up +42% on the projected 2030 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NNVC could reach as high as $6.72, with a base case around $3.96 and support toward $2.52 — roughly +156% from $1.55. Momentum favours further upside here.
Expect NNVC to range from $2.64 to $7.40 through 2033. The $4.27 average target implies a +175% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NNVC price prediction for 2034 points to an average of $4.29 (low $2.58, high $7.60) — a potential gain of +177% on today's $1.55. Momentum favours further upside here.
In 2035, NNVC is projected to trade between $2.67 and $8.24, averaging $4.56 — a potential gain of +194% from today's $1.55. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NanoViricides, Inc.'s 2040 outlook centres on $8.05, within a $4.18 to $15.81 range. That is up +77% on the projected 2035 average. That marks a +420% change versus current levels. Momentum favours further upside here.
By 2050, NNVC could reach as high as $39.99, with a base case around $18.14 and support toward $8.17 — roughly +10.7x from $1.55. Buyers look set to stay in control over this stretch.
Investing $1,000 in NNVC today (≈ 645.16129 NNVC) could be worth
$11,706.12
+$10,706.12 (+1071%) by 2050 · US Dollar
Based on the average projected NNVC price of $18.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NNVCwould be worth at today's price.
$1,000 invested in NNVC on Jul 31, 2025 (≈ 617.283949 NNVC) would be worth
$956.79
-$43.21 (-4.3%) today · 0.96× · US Dollar
Based on a NNVC entry price of $1.62 vs. today's $1.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.48 | $1,047.3 | +4.7% |
| 1 month ago | $1.35 | $1,148.15 | +14.8% |
| 3 months ago | $1.3 | $1,192.31 | +19.2% |
| 6 months ago | $0.98 | $1,581.63 | +58.2% |
| 1 year ago | $1.62 | $956.79 | -4.3% |
| All time (5.0y) ago | $3.91 | $396.42 | -60.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NNVC forecast.
Our base-case forecast reaches $3.10 around 2031.
Implied market cap at $3.10: $79.05M
The multi-year forecast shows a path of variable gains, with the 2026 average price at $1.61 (min $0.85, max $2.10) and 0% ROI, indicating a neutral near term. By 2030, the average rises to $2.24 with a 39.4% ROI and a bullish sentiment; 2040 projects an average of $6.77 with a 320.6% ROI, and 2050 projects an average of $14.63 with an 808.8% ROI and bullish sentiment. The forecast also shows notable steps through 2027–2035, with 2031 average $3.16 (ROI 96%), 2032 $3.58 (ROI 122.3%), 2033 $3.88 (ROI 141.2%), 2034 $3.83 (ROI 137.6%), and 2035 $3.93 (ROI 144%).
These figures imply meaningful upside over the longer term but remain estimates, not guarantees, and are subject to volatility and market risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.24 with a min of $1.48, a max of $3.68, and a 39.4% ROI; sentiment is BULLISH.
Forecasts show bullish sentiment in later years with ROIs such as 96% in 2031, 122.3% in 2032, and 808.8% in 2050, though early 2026 projects 0% ROI. These are estimates and involve volatility.
Yes. The 2040 forecast has a max of $13.72 and an average of $6.77, with a 320.6% ROI, and by 2050 the max is $33.47, indicating reaching higher levels is possible within the forecast horizon.
$1.20 to $2.16.
The current price is $1.61 and the market cap is $41.05M.
NanoViricides, Inc. Community Discussion
0Share your NanoViricides, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.